This inventor holds 1 USPTO granted patent. Top assignee: Oklahoma Medical Research Foundation. Active years: 2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006
Title: Omid Safa Jamilabadi: Innovator in Thrombotic Risk Assessment
Introduction
Omid Safa Jamilabadi is a notable inventor based in Oklahoma City, OK. He has made significant contributions to the field of thrombotic risk assessment through his innovative research and patent.
Latest Patents
Jamilabadi holds a patent for "Thrombotic episode risk assays using oxidized phospholipids." This assay assesses thrombotic risk by utilizing oxidized lipids comprising phospholipids as a membrane source in a clotting assay. The results are compared to an assay using unoxidized phospholipid as a membrane source, both in the presence and absence of activated protein C (APC). This assay can monitor for the presence of antibodies in patients that interfere specifically with the anticoagulant function of APC, indicating the propensity of patients to experience episodes of vein thrombosis or arterial thrombosis.
Career Highlights
Omid Safa Jamilabadi is affiliated with the Oklahoma Medical Research Foundation, where he conducts his research. His work focuses on improving the understanding of thrombotic risks and developing innovative assays to better assess these risks.
Collaborations
Jamilabadi collaborates with Naomi L Esmon, contributing to advancements in the field of thrombotic risk assessment.
Conclusion
Omid Safa Jamilabadi's work in thrombotic risk assessment represents a significant advancement in medical research. His innovative patent and collaboration with esteemed colleagues highlight his commitment to improving patient outcomes in thrombotic conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile